Allergic Rhinoconjunctivitis
Conditions
Keywords
specific immunotherapy, SIT, SLIT, sublingual
Brief summary
Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering from allergic rhinitis/rhinoconjunctivitis with or without bronchial asthma.
Detailed description
Although highly effective, subcutaneous administration of allergens may cause inconvenience in some patients. Alternative routes, e.g. nasal and oral, have therefore been investigated to find an immunotherapy regimen largely accepted by all groups of patients, including children. Sublingual specific immunotherapy (SLIT) may represent a more acceptable route of immunotherapy. It may be an optimal therapy option especially for children because they often fear injections. In this study children are to be treated with a preparation of a grass pollen allergen extract in a water/glycerol solution with phosphate buffered saline in comparison to a symptomatic standard treatment with add on placebo, in order to investigate efficacy and safety of the study drug.
Interventions
In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
Sponsors
Study design
Eligibility
Inclusion criteria
* 4 - \<12 years (at the time of inclusion) * Positive SPT * Positive EAST * Positive CPT
Exclusion criteria
* Serious chronic diseases * Other perennial allergies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes of Symptom-Medication-Score | After 1 year of treatment | The change of the area under the curve of the symptom and medication score (SMS) from the baseline season to the season after 1 year of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the documentation of adverse events (AEs) | Entire treatment period | Safety of treatments during the entire treatment period. |
Countries
Germany